Press Releases

Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy

WATERTOWN, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies that avoid unwanted immunogenicity for the treatment of rare and serious diseases, today announced several presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 10-13, 2017 at the Marriott Wardman Park Hotel in Washington, D.C.

Selecta co-founder Dr. Robert Langer will be the Plenary Speaker at ASGCT’s Presidential Symposium on Friday, May 12, 2017. Dr. Langer is an Institute Professor at the Massachusetts Institute of Technology who has over 1,100 issued and pending patents. He has earned numerous recognitions, including the US National Medal of Science, the US National Medal of Technology and Innovation, and the Queen Elizabeth Prize for Engineering. Among other topics, Dr. Langer is expected to discuss the need for repeat dosing in gene therapy. Selecta is working with various collaborators on two proprietary gene therapy programs that utilize Selecta’s Synthetic Vaccine Particles (SVP™) technology to enable repeat gene therapy doses.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid the immune responses that compromise efficacy and lead to life-threatening complications. Selecta is applying its proprietary Synthetic Vaccine Particles (SVP™) to a range of therapeutic areas in which immunogenicity is a key challenge. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and reduce their debilitating symptoms, including flares and inflammatory arthritis. Further, Selecta’s two proprietary gene therapy product candidates have the potential to enable repeat administration, allowing for dose adjustment in patients and maintenance of therapeutic activity over time. The company is seeking to expand the use of its SVP platform in other areas, such as allergies, autoimmune diseases and vaccines. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com.

Forward-Looking Statements

Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the development of its pipeline, the ability of the company’s SVP platform, including SVP-Rapamycin, to mitigate immune response and create better therapeutic outcomes, the potential treatment applications for products utilizing the SVP platform in areas such as gene therapy, immuno-oncology, allergies, autoimmune diseases and vaccines, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 28, 2017, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.